ArticleAntimicrobial agents and chemotherapy2010
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria.The Cochrane database of systematic reviews · 2025Pooled it
- Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria.The Cochrane database of systematic reviews · 2022Pooled it
- Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria.The Cochrane database of systematic reviews · 2019Pooled it
- Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria.The Cochrane database of systematic reviews · 2014Pooled it
- Trial
- Leucinostatins from fungal extracts block malaria transmission to mosquitoes.Parasites & vectors · 2024Article
- AreBiomedicines · 2024Article
- Diagnosis and management of malaria in the intensive care unit.Journal of intensive medicine · 2024Review
- Toxins from Animal Venoms as a Potential Source of Antimalarials: A Comprehensive Review.Toxins · 2023Review
- Multidisciplinary Investigations of Sustained Malaria Transmission in the Greater Mekong Subregion.The American journal of tropical medicine and hygiene · 2022Article
- Longitudinal ex vivo and molecular trends of chloroquine and piperaquine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia.International journal for parasitology. Drugs and drug resistance · 2021Article
- Daily rhythms of both host and parasite affect antimalarial drug efficacy.Evolution, medicine, and public health · 2021Article
- In Vitro Sensitivity of Pyronaridine in Thai Isolates ofThe American journal of tropical medicine and hygiene · 2018Article
- The Biology ofCold Spring Harbor perspectives in medicine · 2017Review
- Diagnosis and Treatment of Plasmodium vivax Malaria.The American journal of tropical medicine and hygiene · 2016Article
- The Plasmodium falciparum chloroquine resistance transporter is associated with the ex vivo P. falciparum African parasite response to pyronaridine.Parasites & vectors · 2016Article
- Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine.Malaria journal · 2015Article
- Chloroquine efficacy studies confirm drug susceptibility of Plasmodium vivax in Chennai, India.Malaria journal · 2014Article
- Field-based flow cytometry for ex vivo characterization of Plasmodium vivax and P. falciparum antimalarial sensitivity.Antimicrobial agents and chemotherapy · 2013Article
- Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials.Malaria journal · 2013Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 4 countries.
Funding
Abstract
Pyronaridine, a Mannich base antimalarial, has demonstrated high in vivo and in vitro efficacy against chloroquine-resistant Plasmodium falciparum. Although this drug has the potential to become a prominent artemisinin combination therapy, little is known about its efficacy against drug-resistant Plasmodium vivax. The in vitro antimalarial susceptibility of pyronaridine was assessed in multidrug-resistant P. vivax (n = 99) and P. falciparum (n = 90) isolates from Papua, Indonesia, using a schizont maturation assay. The median 50% inhibitory concentration (IC(50)) of pyronaridine was 1.92 nM (range, 0.24 to 13.8 nM) against P. falciparum and 2.58 nM (range, 0.13 to 43.6 nM) against P. vivax, with in vitro susceptibility correlating significantly with chloroquine, amodiaquine, and piperaquine (r(s) [Spearman's rank correlation coefficient] = 0.45 to 0.62; P < 0.001). P. falciparum parasites initially at trophozoite stage had higher IC(50)s of pyronaridine than those exposed at the ring stage (8.9 nM [range, 0.6 to 8.9 nM] versus 1.6 nM [range, 0.6 to 8.9 nM], respectively; P = 0.015), although this did not reach significance for P. vivax (4.7 nM [range, 1.4 to 18.7 nM] versus 2.5 nM [range, 1.4 to 15.6 nM], respectively; P = 0.085). The excellent in vitro efficacy of pyronaridine against both chloroquine-resistant P. vivax and P. falciparum highlights the suitability of the drug as a novel partner for artemisinin-based combination therapy in regions where the two species are coendemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.